GlycoMimetics, Inc.

GlycoMimetics, Inc. is developing novel small molecule drugs
to treat orphan diseases.

 
GlycoMimetics, Inc. In the News
 

The Scientist – February 2012 – Female Frontrunners: How to successfully surmount the challenges women face in becoming biotech industry leaders – featuring Rachel King, CEO & Co-Founder, GlycoMimetics

CNBC Video – January 2012 – Pfizer Q4 Results with GlycoMimetics Mention

FierceBiotech – Pfizer inks $340M rare disease pact with GlycoMimetics

Metro Business Media – Hope for Sickle Cell Patients...GlycoMimetics Paving the Way

BioCentury TV – BIO's James Greenwood, Rachel King of GlycoMimetics and others discuss ideas for transforming biotech landscape

SciBx – Two edges of sickle cell disease

BioCentury TV - GlycoMimetics CEO Rachel King describes how therapeutic discovery tax grants will affect their efforts in sickle cell disease

FierceBiotech – Top 10 Women in Biotech (featuring Rachel King)

Washington Business Journal – GlycoMimetics completes drug trial

Washington Business Journal – GlycoMimetics’ sickle cell drug enters human tests

Washington Business Journal – GlycoMimetics Chief Named to Biotech Institute's Board

Windhover Start-Up Magazine – Glycobiology's Second Wave

The Washington Post – GlycoMimetics' Research Taps Troublesome Carbohydrates to Combat Diseases

Signals Magazine – Glycobiology: Biotech's New Sweet Spot

 
Site Map | Copyright © 2012 | Contact Us